Description

Fortrea’s Hidden Biotech Catalyst: Small & Mid-Sized Sponsors Are Returning!

Fortrea’s first quarter of 2026 showed mixed but generally encouraging operational and financial results, continuing its progression toward growth and margin improvement. The company reported revenue of $636.5 million, reflecting a 2.3% year-over-year decline primarily due to lower pass-through costs and ongoing headwinds in its Functional Service Provider (FSP) offerings. Despite this decline, underlying full-service clinical revenue grew year-over-year, indicating a positive shift in core business activity. Book-to-bill ratios remained elevated at 1.15x for the quarter and 1.05x on a trailing 12-month basis, marking the third consecutive quarter with a book-to-bill above one, signaling improved commercial traction. The weighted backlog stood at $7.8 billion, with cancellations remaining within historical ranges. On the commercial front, Fortrea highlighted growing strength in biotech engagements, notably among small and mid-sized companies focused on oncology, cardiovascular, and RNA-based therapies. An uptick in RFPs from biotech firms and diversification away from large pharma customers were noted.